We are live on ! Find out more

Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
BCYC icon
276
Bicycle Therapeutics
BCYC
$250M
$250M $3.57 0.83%
FATE icon
277
Fate Therapeutics
FATE
$248M
$248M $2.07 0.49%
LXEO icon
278
Lexeo Therapeutics
LXEO
$246M
$246M $3 0.66%
ACIU icon
279
AC Immune
ACIU
$246M
$246M $2.47 0.8%
PALI icon
280
Palisade Bio
PALI
$244M
$244M $1.40 2.1%
GLSI icon
281
Greenwich LifeSciences
GLSI
$243M
$243M $16.57 2.03%
VNDA icon
282
Vanda Pharmaceuticals
VNDA
$242M
$242M $4.01 3.84%
IMRX icon
283
Immuneering
IMRX
$242M
$242M $3.74 0.27%
RCKT icon
284
Rocket Pharmaceuticals
RCKT
$242M
$242M $2.20 5.98%
IKT icon
285
Inhibikase Therapeutics
IKT
$232M
$232M $1.66 2.92%
LYEL icon
286
Lyell Immunopharma
LYEL
$231M
$231M $9.41 2.99%
MGNX icon
287
MacroGenics
MGNX
$229M
$229M $3.59 2.87%
IFRX icon
288
InflaRx
IFRX
$228M
$228M $1.55 0.65%
ZNTL icon
289
Zentalis Pharmaceuticals
ZNTL
$223M
$223M $2.36 1.26%
KROS icon
290
Keros Therapeutics
KROS
$222M
$222M $11.18 1.93%
SLGL icon
291
Sol-Gel Technologies
SLGL
$215M
$215M $65.72 0.14%
BBOT icon
292
BridgeBio Oncology
BBOT
$215M
$215M $2.68 1.47%
ALEC icon
293
Alector
ALEC
$209M
$209M $1.87 5.08%
CAMP icon
294
CAMP4 Therapeutics
CAMP
$206M
$206M $3.29 4.11%
CGEN icon
295
Compugen
CGEN
$201M
$201M $2.12 0.93%
RNAC icon
296
Cartesian Therapeutics
RNAC
$194M
$194M $6.42 0.31%
PRQR icon
297
ProQR Therapeutics
PRQR
$193M
$193M $1.37 0.72%
IVVD icon
298
Invivyd
IVVD
$188M
$188M $0.6393 0.42%
PEPG icon
299
PepGen
PEPG
$188M
$188M $2.72 5.23%
EVMN icon
300
Evommune Inc
EVMN
$188M
$188M $5.17 3.9%
10 11
12
13 14

Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 570 Biotechnology industry stocks tracked by Wall St. Rank, worth a combined $1.28T.

The largest by market cap are Vertex Pharmaceuticals (VRTX) at $133B, Moderna (MRNA) at $98.1B and Regeneron Pharmaceuticals (REGN) at $82.9B.

Among institutional investors, Revolution Medicines (RVMD) drew the most net new fund positions in Q2 2026: 246 funds opened new positions, taking total fund holders up 181 (35%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.